{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:47:29Z","timestamp":1771332449180,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00103-018-2768-1","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T09:39:37Z","timestamp":1529401177000},"page":"1022-1029","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Valproatverordnungen bei M\u00e4dchen und Frauen im geb\u00e4rf\u00e4higen Alter in Deutschland","Prescribing valproate to girls and women of childbearing age in Germany"],"prefix":"10.1007","volume":"61","author":[{"given":"Nadine","family":"Wentzell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Haug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Schink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Engel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Liebentraut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Linder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlies","family":"Onken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarina","family":"Dathe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,19]]},"reference":[{"key":"2768_CR1","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","volume":"15","author":"T Tomson","year":"2016","unstructured":"Tomson T, Battino D, Perucca E (2016) Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a\u00a0time-honoured drug. Lancet Neurol 15:210\u2013218","journal-title":"Lancet Neurol"},{"key":"2768_CR2","volume-title":"S1-Leitlinie Erster epileptischer Anfall und Epilepsien im Erwachsenenalter. Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"CE Elger","year":"2017","unstructured":"Elger CE, Berkenfeld R et al (2017) S1-Leitlinie Erster epileptischer Anfall und Epilepsien im Erwachsenenalter. Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft f\u00fcr Neurologie, Berlin"},{"key":"2768_CR3","volume-title":"S3-Leitlinie zur Diagnostik und Therapie Bipolarer St\u00f6rungen. Langversion","author":"DGBS e.\u202fV.","year":"2012","unstructured":"DGBS e.\u202fV., DGPPN e.\u202fV. (2012) S3-Leitlinie zur Diagnostik und Therapie Bipolarer St\u00f6rungen. Langversion"},{"key":"2768_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010611","author":"M Linde","year":"2013","unstructured":"Linde M, Mulleners WM, Chronicle EP, Mccrory DC (2013) Valproate (valproic acid or sodium valproate or a\u00a0combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. \n                    https:\/\/doi.org\/10.1002\/14651858.CD010611","journal-title":"Cochrane Database Syst Rev"},{"key":"2768_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008544.pub2","author":"PP Pani","year":"2014","unstructured":"Pani PP, Trogu E, Pacini M, Maremmani I (2014) Anticonvulsants for alcohol dependence. Cochrane Database Syst Rev. \n                    https:\/\/doi.org\/10.1002\/14651858.CD008544.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2768_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004028.pub4","author":"Y Wang","year":"2016","unstructured":"Wang Y, Xia J, Helfer B, Li C, Leucht S (2016) Valproate for schizophrenia. Cochrane Database Syst Rev. \n                    https:\/\/doi.org\/10.1002\/14651858.CD004028.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"2768_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.reprotox.2009.02.014","volume":"28","author":"A Ornoy","year":"2009","unstructured":"Ornoy A (2009) Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol 28:1\u201310","journal-title":"Reprod Toxicol"},{"key":"2768_CR8","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1212\/WNL.0000000000001772","volume":"85","author":"T Tomson","year":"2015","unstructured":"Tomson T, Battino D, Bonizzoni E et al (2015) Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology 85:866\u2013872","journal-title":"Neurology"},{"key":"2768_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/ajmg.1320190308","volume":"19","author":"JH DiLiberti","year":"1984","unstructured":"DiLiberti JH, Farndon PA, Dennis NR, Curry CJ (1984) The fetal valproate syndrome. Am J Med Genet 19:473\u2013481","journal-title":"Am J Med Genet"},{"key":"2768_CR10","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1111\/epi.12226","volume":"54","author":"G Veiby","year":"2013","unstructured":"Veiby G, Daltveit AK, Schjolberg S et al (2013) Exposure to antiepileptic drugs in utero and child development: a\u00a0prospective population-based study. Epilepsia 54:1462\u20131472","journal-title":"Epilepsia"},{"key":"2768_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","volume":"12","author":"KJ Meador","year":"2013","unstructured":"Meador KJ, Baker GA, Browning N et\u00a0al (2013) Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a\u00a0prospective observational study. Lancet Neurol 12:244\u2013252","journal-title":"Lancet Neurol"},{"key":"2768_CR12","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/jama.2013.2270","volume":"309","author":"J Christensen","year":"2013","unstructured":"Christensen J, Gronborg TK, Sorensen MJ et\u00a0al (2013) Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 309:1696\u20131703","journal-title":"JAMA"},{"key":"2768_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/jnnp-2012-304270","volume":"84","author":"RL Bromley","year":"2013","unstructured":"Bromley RL, Mawer GE, Briggs M et\u00a0al (2013) The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J\u00a0Neurol Neurosurg Psychiatr 84:637\u2013643","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"2768_CR14","volume-title":"PRAC recommends strengthening the restrictions on the use of valproate in women and girls. Women to be better informed of the risks of valproate use during pregnancy","author":"European Medicines Agency","year":"2014","unstructured":"European Medicines Agency (2014) PRAC recommends strengthening the restrictions on the use of valproate in women and girls. Women to be better informed of the risks of valproate use during pregnancy. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Valproate_and_related_substances_31\/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee\/WC500175214.pdf\n                    \n                  . Zugegriffen: 27. Apr. 2017"},{"key":"2768_CR15","volume-title":"Rote-Hand-Brief: Arzneimittel, die Valproat und -verwandte Substanzen enthalten: Risiko f\u00fcr Anomalien des Neugeborenen","author":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte","year":"2014","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (2014) Rote-Hand-Brief: Arzneimittel, die Valproat und -verwandte Substanzen enthalten: Risiko f\u00fcr Anomalien des Neugeborenen. \n                    https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Arzneimittel\/Pharmakovigilanz\/Risikoinformationen\/RI_rhb\/2014\/valproat-rhb.pdf;jsessionid=5637F8FBA7C8F75CF40681EC63474F6E.2_cid329?__blob=publicationFile&v=2\n                    \n                  . Zugegriffen: 21. Apr. 2017"},{"key":"2768_CR16","volume-title":"Leitfaden f\u00fcr medizinische Fachkr\u00e4fte","author":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte","year":"2014","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (2014) Leitfaden f\u00fcr medizinische Fachkr\u00e4fte. \n                    https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Arzneimittel\/Pharmakovigilanz\/Risikoinformationen\/RI_rhb\/2014\/valproat-leitfaden.pdf;jsessionid=7FA3A5CE34E2BB6827DA2E5FD3C65B70.2_cid354?__blob=publicationFile&v=2\n                    \n                  . Zugegriffen: 10. Mai 2017"},{"key":"2768_CR17","volume-title":"Patienteninformationsbrosch\u00fcre \u2013 Valproat","author":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte","year":"2014","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (2014) Patienteninformationsbrosch\u00fcre \u2013 Valproat. \n                    https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Arzneimittel\/Pharmakovigilanz\/Risikoinformationen\/RI_rhb\/2014\/valproat-patientenbrosch.pdf;jsessionid=7FA3A5CE34E2BB6827DA2E5FD3C65B70.2_cid354?__blob=publicationFile&v=2\n                    \n                  . Zugegriffen: 10. Mai 2017"},{"key":"2768_CR18","volume-title":"Einf\u00fchrung einer Patientenkarte f\u00fcr Arzneimittel, die Valproat und verwandte Substanzen enthalten","author":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte","year":"2017","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (2017) Einf\u00fchrung einer Patientenkarte f\u00fcr Arzneimittel, die Valproat und verwandte Substanzen enthalten. \n                    https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Arzneimittel\/Pharmakovigilanz\/Risikoinformationen\/RisikoBewVerf\/s-z\/valproat_patientenkarte_bescheid.pdf;jsessionid=EE3B9B87586BC1CBBDB7472B337FD8CE.2_cid344?__blob=publicationFile&v=3\n                    \n                  . Zugegriffen: 8. Aug. 2017"},{"key":"2768_CR19","volume-title":"Patienten-Erinnerungskarte: Valproat enthaltende Arzneimittel und Schwangerschaft","author":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte","year":"2017","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (2017) Patienten-Erinnerungskarte: Valproat enthaltende Arzneimittel und Schwangerschaft. \n                    http:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Arzneimittel\/Pharmakovigilanz\/Risikoinformationen\/RI_rhb\/2017\/info-valproat-und-verwandte-substanzen2.pdf?__blob=publicationFile&v=2\n                    \n                  . Zugegriffen: 8. Aug. 2017"},{"key":"2768_CR20","volume-title":"Informationsbrief zur Einf\u00fchrung einer Patientenkarte f\u00fcr Arzneimittel, die Valproat und verwandte Substanzen enthalten","author":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte","year":"2017","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (2017) Informationsbrief zur Einf\u00fchrung einer Patientenkarte f\u00fcr Arzneimittel, die Valproat und verwandte Substanzen enthalten. \n                    http:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Arzneimittel\/Pharmakovigilanz\/Risikoinformationen\/RI_rhb\/2017\/info-valproat-und-verwandte-substanzen.pdf?__blob=publicationFile&v=3\n                    \n                  . Zugegriffen: 8. Aug. 2017"},{"key":"2768_CR21","volume-title":"Depakine. Frankreich will Opfer von Pharma-Skandal entsch\u00e4digen","author":"Deutsche Apotheker Zeitung","year":"2016","unstructured":"Deutsche Apotheker Zeitung (2016) Depakine. Frankreich will Opfer von Pharma-Skandal entsch\u00e4digen. \n                    https:\/\/www.deutsche-apotheker-zeitung.de\/news\/artikel\/2016\/11\/16\/frankreich-will-opfer-von-pharma-skandal-entschaedigen\n                    \n                  . Zugegriffen: 6. Sept. 2017"},{"key":"2768_CR22","volume-title":"Exposition \u00e0 l\u2019acide valpro\u00efque et ses d\u00e9riv\u00e9s au cours de la grossesse en France de 2007 \u00e0 2014: une \u00e9tude observationnelle sur les donn\u00e9es du SNIIRAM","author":"Agence Nationale De S\u00e9curit\u00e9 Du M\u00e9dicament Et Des Produitrs De Sant\u00e9 & Securit\u00e9 Sociale L\u2019assurance Maladie Caisse Nationale","year":"2016","unstructured":"Agence Nationale De S\u00e9curit\u00e9 Du M\u00e9dicament Et Des Produitrs De Sant\u00e9 & Securit\u00e9 Sociale L\u2019assurance Maladie Caisse Nationale (2016) Exposition \u00e0 l\u2019acide valpro\u00efque et ses d\u00e9riv\u00e9s au cours de la grossesse en France de 2007 \u00e0 2014: une \u00e9tude observationnelle sur les donn\u00e9es du SNIIRAM. \n                    http:\/\/social-sante.gouv.fr\/IMG\/pdf\/rapport_etude_utilisation_vpa_24.08_version_def.pdf\n                    \n                  . Zugegriffen: 19. Apr. 2017"},{"key":"2768_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/pds.1545","volume":"17","author":"I Pigeot","year":"2008","unstructured":"Pigeot I, Ahrens W (2008) Establishment of a\u00a0pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf 17:215\u2013223","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2768_CR24","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1161\/STROKEAHA.111.000811","volume":"44","author":"E Garbe","year":"2013","unstructured":"Garbe E, Kreisel SH, Behr S (2013) Risk of subarachnoid hemorrhage and early case fatality associated with outpatient antithrombotic drug use. Stroke 44:2422\u20132426","journal-title":"Stroke"},{"key":"2768_CR25","volume-title":"Fortschreibung des Bev\u00f6lkerungsstandes Deutschland","author":"Statistisches Bundesamt (Destatis)","year":"2017","unstructured":"Statistisches Bundesamt (Destatis) (2017) Fortschreibung des Bev\u00f6lkerungsstandes Deutschland. \n                    https:\/\/www-genesis.destatis.de\/genesis\/online\/data;jsessionid=AD44FE8EED80FAEC0337C0C700FA3AA2.tomcat_GO_1_2?operation=abruftabelleBearbeiten&levelindex=2&levelid=1505821138012&auswahloperation=abruftabelleAuspraegungAuswaehlen&auswahlverzeichnis=ordnungsstruktur&auswahlziel=werteabruf&selectionname=12411-0006&auswahltext=&nummer=5&variable=2&name=GES&werteabruf=Werteabruf\n                    \n                  . Zugegriffen: 19. Sept. 2017"},{"key":"2768_CR26","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1056\/NEJMoa0907328","volume":"362","author":"J Jentink","year":"2010","unstructured":"Jentink J, Loane MA, Dolk H et\u00a0al (2010) Valproic acid monotherapy in pregnancy and major congenital malformations. N\u00a0Engl J Med 362:2185\u20132193","journal-title":"N Engl J Med"},{"key":"2768_CR27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00404-009-1112-2","volume":"281","author":"C Schaefer","year":"2010","unstructured":"Schaefer C, Meister R, Weber-Schoendorfer C (2010) Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy. Arch Gynecol Obstet 281:221\u2013227","journal-title":"Arch Gynecol Obstet"},{"key":"2768_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.seizure.2016.01.019","volume":"36","author":"S Murphy","year":"2016","unstructured":"Murphy S, Bennett K, Doherty CP (2016) Prescribing trends for sodium valproate in Ireland. Seizure 36:44\u201348","journal-title":"Seizure"},{"key":"2768_CR29","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/epi.13021","volume":"56","author":"T Tomson","year":"2015","unstructured":"Tomson T, Marson A, Boon P et\u00a0al (2015) Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia 56:1006\u20131019","journal-title":"Epilepsia"},{"key":"2768_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/CLEP.S118336","volume":"9","author":"I Petersen","year":"2017","unstructured":"Petersen I, Collings SL, Mccrea RL et\u00a0al (2017) Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies. Clin Epidemiol 9:95\u2013103","journal-title":"Clin Epidemiol"},{"key":"2768_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12916-017-0845-1","volume":"15","author":"AA Veroniki","year":"2017","unstructured":"Veroniki AA, Cogo E, Rios P et al (2017) Comparative safety of anti-epileptic drugs during pregnancy: a\u00a0systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med 15:95","journal-title":"BMC Med."},{"key":"2768_CR32","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa1612222","volume":"376","author":"E Patorno","year":"2017","unstructured":"Patorno E, Huybrechts KF, Bateman BT et\u00a0al (2017) Lithium use in pregnancy and the risk of cardiac malformations. N\u00a0Engl J Med 376:2245\u20132254","journal-title":"N Engl J Med"},{"key":"2768_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/bcpt.12372","volume":"116","author":"ZN Ennis","year":"2015","unstructured":"Ennis ZN, Damkier P (2015) Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review. Basic Clin Pharmacol Toxicol 116:315\u2013320","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2768_CR34","volume-title":"Behandlung der Migr\u00e4ne und idiopathischer Kopfschmerzsyndrome in Schwangerschaft und Stillzeit","author":"U Bingel","year":"2009","unstructured":"Bingel U, Evers S, Reister F, Ebinger F, Paulus W (2009) Behandlung der Migr\u00e4ne und idiopathischer Kopfschmerzsyndrome in Schwangerschaft und Stillzeit. Deutsche Migr\u00e4ne- und Kopfschmerzgesellschaft (DMKG), Kiel"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00103-018-2768-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-018-2768-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-018-2768-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T23:15:45Z","timestamp":1560899745000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00103-018-2768-1"}},"subtitle":["Untersuchung zeitlicher Trends basierend auf Versichertendaten","Analysis of trends based on claims data"],"short-title":[],"issued":{"date-parts":[[2018,6,19]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["2768"],"URL":"https:\/\/doi.org\/10.1007\/s00103-018-2768-1","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,19]]},"assertion":[{"value":"19 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"N.\u00a0Wentzell, U.\u00a0Haug, T.\u00a0Schink, S.\u00a0Engel, J.\u00a0Liebentraut, R.\u00a0Linder, M.\u00a0Onken, C.\u00a0Schaefer und K.\u00a0Dathe geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}